Fly News Breaks for September 26, 2019
Sep 26, 2019 | 07:12 EDT
As previously reported, Wedbush analyst Laura Chico started coverage of Denali Therapeutics with a Neutral and $19.price target, citing valuation. As much of the CNS therapeutics sector undergoes a renaissance of sorts, the analyst sees Denali at the forefront of this trend via its focus on genetic drivers of disease, and early incorporation of target engagement assessments. But while Chico is enthusiastic on its programs and strategy, she awaits a better entry point.
News For DNLI From the Last 2 Days
There are no results for your query DNLI